my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Merus B.V. announced today that it has been granted the first European patent covering its Oligoclonics® technology from a patent family that already comprises 4 issued US patents. The Oligoclonics® technology entails the manufacturing of at least three antibodies with different specificities by a s more
arGEN-X announced that it has entered into an alliance with Shire to create novel therapeutic antibody products against multiple targets submitted by Shire. Using its SIMPLE Antibody™ discovery technology, arGEN-X will isolate and characterize human antibodies against the targets that Shire has iden more
Genmab A/S announced it had reached the second pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the second milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders of the c more
As one of the leading public biotech companies in Europe, we are committed to developing the medicines of the future. Building on our portfolio of innovative antibody technologies, we are actively pursuing new therapeutic approaches in close collaboration with the world‘s foremost pharmaceutical com more
In solid tumors, angiogenesis occurs in the setting of a defective vasculature and impaired lymphatic drainage that is associated with increased vascular permeability and enhanced tumor permeability. These universal aspects of the tumor microenvironment can have a marked influence on intratumoral dr more
Abstract Therapeutic antibody processing and purification involve several steps, potentially inducing antibody aggregation. Currently, aggregate monitoring mainly involves chromatography, SDS‐PAGE and light scattering. In this study, the feasibility of mid infrared spectroscopy (MIR) for quantif more
Laboratories all over the world conduct research aimed at developing novel strategies to treat cancer. The approaches include innovative chemotherapy and prodrug agents, therapeutic antibodies, immunotherapies, nanoparticle-based approaches, targeted ultrasound, photodynamic therapy, radiation thera more
MorphoSys AG (MorphoSys) is a biotechnology company engaged in the discovery and development of novel antibodies for therapeutic, diagnostic and research applications. The company operates its business through two operating segments, Therapeutic Antibodies unit which engages in the development of dr more
A A Home About Us Investors Management Board of Directors Scientific Advisory Board Technologies Antibodies Overview Intellectual Property Glossary Partnering Press Room Career Contact Maps & Directions Basel Site Maps & Directions Jena Site Fully human antibodies for any target 4-Antibody’s proprie more
 Home Company About us Management Supervisory Board Advisory Board Finances Careers Technology Overview Fcab™ mAb² Products Business Development News Contact News Welcome to f-star f-star raises € 8m in an Extended Series A Financing co-led by MP Healthcare Venture Management and Merck Sero more
Bringing Innovation to Life Home About Us Corporate Profile Mission and Vision Board of Directors Management Team Organisation Structure Our Affiliations Services Cell Line Development Antibody Services Process Development cGMP Biomanufacturing Training Contract Research QMRA Quality Assurance Quali more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
